Figure 1. a–b: Proportion of post-menopausal women commencing different endocrine therapies, by specified characteristics, and stratified for tumour size.

1a includes women commencing therapy between January 2004-December 2010. 1b is restricted to women commencing therapy between December 2005-December 2010 to reflect practice after the subsidy restriction changes. *Difference of P<0.05 in the proportion of women commencing tamoxifen. ^†Difference of P<0.05 in the proportion of women commencing anastrozole. ^‡ Difference of P<0.05 in the proportion of women commencing letrozole.